US equities saw a mixed close, with the Dow and S&P 500 advancing after August's PCE inflation data met expectations, providing some market relief despite inflation remaining above the Fed's target. However, gains were moderated by unexpectedly pessimistic September consumer sentiment and President Trump's new threat of 100% tariffs on branded drug imports and other goods, which introduced fresh uncertainty and impacted global pharmaceutical stocks.
US equity markets displayed a divergent performance, with the Dow Jones Industrial Average rising 0.4% while the tech-focused Nasdaq Composite fell 0.16%, reflecting a complex interplay of macroeconomic data and geopolitical risk. A key source of relief for investors was the August Personal Consumption Expenditures (PCE) report, where the core index rose 2.9% year-over-year, meeting expectations and assuaging fears of an upside inflation surprise. However, this relief was tempered by the fact that inflation remains well above the Federal Reserve's 2% target. Gains were further capped by an unexpectedly pessimistic University of Michigan consumer sentiment survey for September and the introduction of significant trade uncertainty. President Trump's threat of a 100% tariff on imported branded drugs from companies without US manufacturing facilities has already negatively impacted European and Asian pharmaceutical stocks and introduces substantial sector-specific risk. This, combined with new tariffs on trucks and furniture effective October 1, adds to existing market anxieties over a potential government shutdown and the sustainability of the AI-driven tech rally, positioning the S&P 500 for its first weekly loss of the month.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment